Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890515735> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2890515735 endingPage "11515" @default.
- W2890515735 startingPage "11515" @default.
- W2890515735 abstract "11515 Background: Disruption of angiogenesis substantially enhances the efficacy of immune-based cancer therapies. The combination of an antiangiogenic drug (sunitinib or pazopanib) plus anti- PD1 (nivolumab) exhibited both higher activity and toxicity compared with antiangiogenic drug alone in renal cell carcinoma (RCC). We hypothesized that sunitinib (SU) and nivolumab (NI) could be synergistic in some sarcoma subtypes and the toxicity profile could be different from RCC. We present the results of phase I part of the combination of SU-NI in advanced sarcoma patients (pts). Methods: Pretreated progressing pts, ECOG 0-1 and diagnosed with UPS, synovial sarcoma (SS), clear cell sarcoma (CCS), angiosarcoma (AS), epithelioid hemangioendothelioma (EH), solitary fibrous tumor (SFT), epithelioid sarcoma (ES), osteosarcoma (OS), Ewing sarcoma (EWS) or dedifferentiated chondrosarcoma (DCh) were eligible. SU 37.5 mg/d as induction was given for the first 14 days. The dose-finding stage (from day 15 to 45) would be completed when 10 dose limiting toxicity (DLT)-evaluated pts had been treated with DLT rate < 0.33. Two level- doses were designed: (0 initial) SU 37.5 mg/d or (-1) SU 25 mg/d along with NI 3 mg/kg/2w for both. SU-NI was maintained up to progression or intolerance. Results: From May to October 2017, 16 pts (M/F 10/6), median age 38y (25-78) were enrolled. Diagnosis was: CSS in 4 (25%), ASPS in 3 (19%); AS, OS, SS (2 each, 12.5%); UPS, extraskeletal OS and Ch (1 each, 6%). There were three DLT in the first 6 pts at dose level 0 (G3 fatigue in 2 and G4 septic shock) and 1 DLT in the following 10 pts at level -1 (febrile neutropenia). G3/4 toxicity: fatigue 25%, thrombocytopenia 19%, mucositis 13% and neutropenia 13%. There were 6 RECIST PR (42.8%), 4 SD (2 of them 25% of shrinkage) and 4 PD in 14 evaluable pts. PR occurred in 2 CCS and in one of AS, Ch, SS, ASPS while 2 cases (ASPS and UPS) shrank 25%. Conclusions: At the RDP2 (SU 25 mg/d and NI 3 mg/kg/2w), SU-NI is a feasible combination with manageable toxicity. SU-NI has induced objective responses in several sarcoma subtypes. The study is currently on a phase II part. Clinical trial information: NCT03277924." @default.
- W2890515735 created "2018-09-27" @default.
- W2890515735 creator A5001235160 @default.
- W2890515735 creator A5003857662 @default.
- W2890515735 creator A5013226419 @default.
- W2890515735 creator A5020381519 @default.
- W2890515735 creator A5030814587 @default.
- W2890515735 creator A5033029074 @default.
- W2890515735 creator A5040082039 @default.
- W2890515735 creator A5065147068 @default.
- W2890515735 creator A5067902486 @default.
- W2890515735 creator A5080548972 @default.
- W2890515735 creator A5080626646 @default.
- W2890515735 creator A5081736939 @default.
- W2890515735 creator A5082287639 @default.
- W2890515735 date "2018-05-20" @default.
- W2890515735 modified "2023-10-16" @default.
- W2890515735 title "IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part." @default.
- W2890515735 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.11515" @default.
- W2890515735 hasPublicationYear "2018" @default.
- W2890515735 type Work @default.
- W2890515735 sameAs 2890515735 @default.
- W2890515735 citedByCount "8" @default.
- W2890515735 countsByYear W28905157352019 @default.
- W2890515735 countsByYear W28905157352020 @default.
- W2890515735 countsByYear W28905157352021 @default.
- W2890515735 countsByYear W28905157352022 @default.
- W2890515735 crossrefType "journal-article" @default.
- W2890515735 hasAuthorship W2890515735A5001235160 @default.
- W2890515735 hasAuthorship W2890515735A5003857662 @default.
- W2890515735 hasAuthorship W2890515735A5013226419 @default.
- W2890515735 hasAuthorship W2890515735A5020381519 @default.
- W2890515735 hasAuthorship W2890515735A5030814587 @default.
- W2890515735 hasAuthorship W2890515735A5033029074 @default.
- W2890515735 hasAuthorship W2890515735A5040082039 @default.
- W2890515735 hasAuthorship W2890515735A5065147068 @default.
- W2890515735 hasAuthorship W2890515735A5067902486 @default.
- W2890515735 hasAuthorship W2890515735A5080548972 @default.
- W2890515735 hasAuthorship W2890515735A5080626646 @default.
- W2890515735 hasAuthorship W2890515735A5081736939 @default.
- W2890515735 hasAuthorship W2890515735A5082287639 @default.
- W2890515735 hasConcept C121608353 @default.
- W2890515735 hasConcept C126322002 @default.
- W2890515735 hasConcept C142724271 @default.
- W2890515735 hasConcept C143998085 @default.
- W2890515735 hasConcept C2776302905 @default.
- W2890515735 hasConcept C2776910622 @default.
- W2890515735 hasConcept C2777472916 @default.
- W2890515735 hasConcept C2777701055 @default.
- W2890515735 hasConcept C2778256501 @default.
- W2890515735 hasConcept C2778439243 @default.
- W2890515735 hasConcept C2778629024 @default.
- W2890515735 hasConcept C2779490328 @default.
- W2890515735 hasConcept C2780030458 @default.
- W2890515735 hasConcept C2781113665 @default.
- W2890515735 hasConcept C2909636867 @default.
- W2890515735 hasConcept C71924100 @default.
- W2890515735 hasConcept C90924648 @default.
- W2890515735 hasConceptScore W2890515735C121608353 @default.
- W2890515735 hasConceptScore W2890515735C126322002 @default.
- W2890515735 hasConceptScore W2890515735C142724271 @default.
- W2890515735 hasConceptScore W2890515735C143998085 @default.
- W2890515735 hasConceptScore W2890515735C2776302905 @default.
- W2890515735 hasConceptScore W2890515735C2776910622 @default.
- W2890515735 hasConceptScore W2890515735C2777472916 @default.
- W2890515735 hasConceptScore W2890515735C2777701055 @default.
- W2890515735 hasConceptScore W2890515735C2778256501 @default.
- W2890515735 hasConceptScore W2890515735C2778439243 @default.
- W2890515735 hasConceptScore W2890515735C2778629024 @default.
- W2890515735 hasConceptScore W2890515735C2779490328 @default.
- W2890515735 hasConceptScore W2890515735C2780030458 @default.
- W2890515735 hasConceptScore W2890515735C2781113665 @default.
- W2890515735 hasConceptScore W2890515735C2909636867 @default.
- W2890515735 hasConceptScore W2890515735C71924100 @default.
- W2890515735 hasConceptScore W2890515735C90924648 @default.
- W2890515735 hasIssue "15_suppl" @default.
- W2890515735 hasLocation W28905157351 @default.
- W2890515735 hasOpenAccess W2890515735 @default.
- W2890515735 hasPrimaryLocation W28905157351 @default.
- W2890515735 hasRelatedWork W1985067973 @default.
- W2890515735 hasRelatedWork W2020387213 @default.
- W2890515735 hasRelatedWork W2309303154 @default.
- W2890515735 hasRelatedWork W2467309414 @default.
- W2890515735 hasRelatedWork W2792518534 @default.
- W2890515735 hasRelatedWork W2890515735 @default.
- W2890515735 hasRelatedWork W3087328364 @default.
- W2890515735 hasRelatedWork W3109577649 @default.
- W2890515735 hasRelatedWork W3171843848 @default.
- W2890515735 hasRelatedWork W4212986922 @default.
- W2890515735 hasVolume "36" @default.
- W2890515735 isParatext "false" @default.
- W2890515735 isRetracted "false" @default.
- W2890515735 magId "2890515735" @default.
- W2890515735 workType "article" @default.